Insider · SEC Form 4 filer
Jonathan Schechter
Companies
Where they file as an insider
PharmaCyte Biotech (PMCB) Director Latest filing Jan 7, 2026
Oblong (OBLG) Director Latest filing Nov 14, 2025
TAO Synergies (TAOX) Director Latest filing Jun 30, 2025
Track record
Did their buys beat the typical stock?
Open-market buys6
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check0
Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.
PharmaCyte Biotech (PMCB) Bought Jan 5–7, 2026 · $48.2K · 60,000 shares Behind typical Mar 31, 2026 $0.67 → Sep 30, 2026 $0.41 · −38.3% (typical stock +1.7%)
Oblong (OBLG) Bought Nov 14, 2025 · $19.1K · 10,000 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2025 and Jun 30, 2026.
Oblong (OBLG) Bought Sep 16–17, 2025 · $40.8K · 15,000 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2025 and Mar 31, 2026.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.